Henry Schein (HSIC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Henry Schein (HSIC) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
HSIC Q4 Earnings & Revenues Beat Estimates, Margins Down
Henry Schein tops Q4 estimates with 7.8% sales growth, but margin contraction tempers strong equipment, specialty and tech gains.
Henry Schein (HSIC) Earnings Expected to Grow: Should You Buy?
Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Henry Schein Q4 Earnings Preview: What's in Store for the Stock?
HSIC gears up for Q4 results, with revenues seen rising 4.5% and strength across dental, medical and tech segments shaping expectations.
Henry Schein, Inc. (HSIC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Henry Schein, Inc. (HSIC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
HSIC or SAUHY: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Henry Schein (HSIC) or Straumann Holding AG (SAUHY). But which of these two companies is the best option for those looking for undervalued stocks?
Why Is Henry Schein (HSIC) Up 1.2% Since Last Earnings Report?
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock?
Henry Schein, Inc. (HSIC) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Henry Schein, Inc. (HSIC) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
HSIC Stock Benefits From Expanded Partnership With vVARDIS
Henry Schein gains exclusive U.S. rights to Curodont, expanding its vVARDIS partnership and boosting expectations for a Dental business rebound.
HSIC Stock Set to Benefit From Henry Schein One's Workflow Launch
HSIC gains momentum as Henry Schein One rolls out AI-powered dental workflows unveiled at the Greater New York Dental Meeting.
Henry Schein, Inc. (HSIC) Presents at Jefferies London Healthcare Conference 2025 Transcript
Henry Schein, Inc. ( HSIC ) Jefferies London Healthcare Conference 2025 November 18, 2025 9:30 AM EST Company Participants Stanley Bergman - Executive Chairman & CEO Andrea Albertini - Chief Executive Officer of Global Distribution & Technology Graham Stanley - VP of Investor Relations & Strategic Finance Project Officer Conference Call Participants Michael Sarcone - Jefferies LLC, Research Division Presentation Michael Sarcone Jefferies LLC, Research Division Hi, everyone. My name is Mike Sarcone.
